Generic placeholder image

Current Neuropharmacology

Author(s): Aurora Zanghì, Diana Ferraro, Graziella Callari, Paola Valentino, Franco Granella, Francesco Patti, Giacomo Lus, Simona Bonavita, Maria Claudia Moretti, Carlo Avolio and Emanuele D’Amico*

DOI: 10.2174/1570159X22666231002142709

DownloadDownload PDF Flyer Cite As
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience

Page: [339 - 345] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID).

Methods: We collect real-world data on patients with primary progressive MS (PPMS) treated with Ocrelizumab (OCR) during the COVID’19 pandemic. The observation period in which the standard interval dosing (SID) or EID occurred (always a maintenance cycle, 600 mg) was from January 2020 to June 2021. All patients had two infusions during the observation period. Our first aim was to compare confirmed disability progression (CDP) between SID and EID patients.

Results: From a total cohort of 410 patients treated with OCR, 96 patients fulfilled the inclusion criteria. All patients received two infusions during the index window, 71 received only SID infusions whilst 25 received at least one EID infusion throughout the entire follow-up. During the entire available follow-up (median 10 months, IQR 7-11), CDP was recorded in 5 patients (3/71, 4.2% SID and 2/25, 8% EID, V-Cramer = 0.141, p-value = 0.167). EID regimen did not influence the risk of CDP during the investigated follow up.

Conclusion: In our multicentre real-world cohort, the EID regimen in PPMS patients did not result in increased CDP during the available follow-up.

Graphical Abstract

[1]
Rolfes, L.; Pawlitzki, M.; Pfeuffer, S.; Nelke, C.; Lux, A.; Pul, R. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol. Neuroimmunol. Neuroinflamm., 2021, 8(5), e1035.
[http://dx.doi.org/10.1212/NXI.0000000000001035] [PMID: 34261812]
[2]
Bar-Or, A.; Calabresi, P.A.J.; Arnold, D.; Markowitz, C.; Shafer, S.; Kasper, L.H.; Waubant, E.; Gazda, S.; Fox, R.J.; Panzara, M.; Sarkar, N.; Agarwal, S.; Smith, C.H. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann. Neurol., 2008, 63(3), 395-400.
[http://dx.doi.org/10.1002/ana.21363] [PMID: 18383069]
[3]
D’Amico, E.; Zanghì, A.; Chisari, C.G.; Fermo, S.L.; Toscano, S.; Arena, S.; Patti, F.; Zappia, M. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Mult. Scler. Relat. Disord., 2019, 27, 324-326.
[http://dx.doi.org/10.1016/j.msard.2018.09.041] [PMID: 30471585]
[4]
Furlan, A.; Forner, G.; Cipriani, L.; Vian, E.; Rigoli, R.; Gherlinzoni, F.; Scotton, P. COVID-19 in B cell-depleted patients after rituximab: A diagnostic and therapeutic challenge. Front. Immunol., 2021, 12, 763412.
[http://dx.doi.org/10.3389/fimmu.2021.763412] [PMID: 34804051]
[5]
D’Amico, E.; Zanghì, A.; Gastaldi, M.; Patti, F.; Zappia, M.; Franciotta, D. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun. Rev., 2019, 18(7), 665-672.
[http://dx.doi.org/10.1016/j.autrev.2019.05.003] [PMID: 31059839]
[6]
Schiavetti, I.; Ponzano, M.; Signori, A.; Bovis, F.; Carmisciano, L.; Sormani, M.P. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult. Scler. Relat. Disord., 2022, 57, 103358.
[http://dx.doi.org/10.1016/j.msard.2021.103358] [PMID: 35158467]
[7]
Simpson-Yap, S.; De Brouwer, E.; Kalincik, T.; Rijke, N.; Hillert, J.A.; Walton, C.; Edan, G.; Moreau, Y.; Spelman, T.; Geys, L.; Parciak, T.; Gautrais, C.; Lazovski, N.; Pirmani, A.; Ardeshirdavanai, A.; Forsberg, L.; Glaser, A.; McBurney, R.; Schmidt, H.; Bergmann, A.B.; Braune, S.; Stahmann, A.; Middleton, R.; Salter, A.; Fox, R.J.; van der Walt, A.; Butzkueven, H.; Alroughani, R.; Ozakbas, S.; Rojas, J.I.; van der Mei, I.; Nag, N.; Ivanov, R.; Sciascia do Olival, G.; Dias, A.E.; Magyari, M.; Brum, D.; Mendes, M.F.; Alonso, R.N.; Nicholas, R.S.; Bauer, J.; Chertcoff, A.S.; Zabalza, A.; Arrambide, G.; Fidao, A.; Comi, G.; Peeters, L. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology, 2021, 97(19), e1870-e1885.
[http://dx.doi.org/10.1212/WNL.0000000000012753] [PMID: 34610987]
[8]
Sormani, M.P.; De Rossi, N.; Schiavetti, I.; Carmisciano, L.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; Trojano, M.; Zaratin, P.; Tedeschi, G.; Comi, G.; Battaglia, M.A.; Patti, F.; Salvetti, M.; Nozzolillo, A.; Bellacosa, A.; Protti, A.; Di Sapio, A.; Signori, A.; Petrone, A.; Bisecco, A.; Iovino, A.; Dutto, A.; Repice, A.M.; Conte, A.; Bertolotto, A.; Bosco, A.; Gallo, A.; Zito, A.; Sartori, A.; Giometto, B.; Tortorella, C.; Antozzi, C.; Pozzilli, C.; Mancinelli, C.R.; Zanetta, C.; Cordano, C.; Cordioli, C.; Scandellari, C.; Guaschino, C.; Gasperini, C.; Solaro, C.; Fioretti, C.; Bezzini, D.; Marastoni, D.; Paolicelli, D.; Vecchio, D.; Landi, D.; Bucciantini, E.; Pedrazzoli, E.; Signoriello, E.; Sbragia, E.; Susani, E.L.; Curti, E.; Milano, E.; Marinelli, F.; Camilli, F.; Boneschi, F.M.; Govone, F.; Bovis, F.; Calabria, F.; Caleri, F.; Rinaldi, F.; Vitetta, F.; Corea, F.; Crescenzo, F.; Patti, F.; Teatini, F.; Tabiadon, G.; Granella, F.; Boffa, G.; Lus, G.; Brichetto, G.; Comi, G.; Tedeschi, G.; Maniscalco, G.T.; Borriello, G.; De Luca, G.; Konrad, G.; Vaula, G.; Marfia, G.A.; Mallucci, G.; Liberatore, G.; Salemi, G.; Miele, G.; Sibilia, G.; Pesci, I.; Schiavetti, I.; Brambilla, L.; Lopiano, L.; Sinisi, L.; Pasquali, L.; Saraceno, L.; Carmisciano, L.; Chiveri, L.; Mancinelli, L.; Moiola, L.; Grimaldi, L.M.E.; Caniatti, L.M.; Capobianco, M.; Cava, M.D.; Onofrj, M.; Rovaris, M.; Salvetti, M.; Vercellino, M.; Bragadin, M.M.; Buccafusca, M.; Buscarinu, M.C.; Celani, M.G.; Grasso, M.G.; Stromillo, M.L.; Petracca, M.; Amato, M.P.; Sormani, M.P.; L’Episcopo, M.R.; Sessa, M.; Ferrò, M.T.; Trojano, M.; Ercolani, M.V.; Bianco, M.; Re, M.L.; Vianello, M.; Clerico, M.; Battaglia, M.A.; Napoli, M.; Ponzano, M.; Radaelli, M.; Conti, M.Z.; Calabrese, M.; Mirabella, M.; Filippi, M.; Inglese, M.; Lucchini, M.; Pozzato, M.; Danni, M.C.; Zaffaroni, M.; Zampolini, M.; Ponzio, M.; De Riz, M.; De Rossi, N.; De Stefano, N.; Cavalla, P.; De Mitri, P.; Grossi, P.; Zaratin, P.; Confalonieri, P.; Gallo, P.; Immovilli, P.; Ragonese, P.; Sola, P.; Annovazzi, P.; Iaffaldano, P.; Nardone, R.; Cerqua, R.; Clerici, R.; Lanzillo, R.; Motta, R.; Balgera, R.; Bergamaschi, R.; Totaro, R.; Iodice, R.; Capra, R.; Marangoni, S.; Realmuto, S.; Cottone, S.; Montepietra, S.; Rasia, S.; Arena, S.; Bucello, S.; Banfi, S.; Bonavita, S.; Malucchi, S.; Tonietti, S.; Vollaro, S.; Cordera, S.; Aguglia, U.; Clerici, V.T.; Barcella, V.; Bergamaschi, V.; Morra, V.B.; Dattola, V.; Mantero, V. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann. Neurol., 2021, 89(4), 780-789.
[http://dx.doi.org/10.1002/ana.26028] [PMID: 33480077]
[9]
Giovannoni, G. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult. Scler. Relat. Disord., 2020, 41, 102135.
[http://dx.doi.org/10.1016/j.msard.2020.102135] [PMID: 32339915]
[10]
Hada, M.; Mosholder, A.D.; Leishear, K.; Perez-Vilar, S. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol. Sci., 2022, 43(3), 1557-1567.
[http://dx.doi.org/10.1007/s10072-021-05846-3] [PMID: 35006442]
[11]
Sharifian-Dorche, M.; Sahraian, M.A.; Fadda, G.; Osherov, M.; Sharifian-Dorche, A.; Karaminia, M.; Saveriano, A.W.; La Piana, R.; Antel, J.P.; Giacomini, P.S. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult. Scler. Relat. Disord., 2021, 50, 102800.
[http://dx.doi.org/10.1016/j.msard.2021.102800] [PMID: 33578206]
[12]
Baba, C.; Yigit, P.; Dastan, S.; Hancer, P.; Sagici, O.; Ozakbas, S.; Abasiyanik, Z. Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic. Neurol. Clin. Neurosci., 2022, 10(1), 3-8.
[http://dx.doi.org/10.1111/ncn3.12561] [PMID: 34909197]
[13]
Silveira, C.; Guedes, R.; Maia, D.; Curral, R.; Coelho, R. Neuropsychiatric symptoms of multiple sclerosis: State of the art. Psychiatry Investig., 2019, 16(12), 877-888.
[http://dx.doi.org/10.30773/pi.2019.0106] [PMID: 31805761]
[14]
Available from:https://www.aifa.gov.it/sites/default/files/Ocrevus.pdf
[15]
Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; Fujihara, K.; Galetta, S.L.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Marrie, R.A.; Miller, A.E.; Miller, D.H.; Montalban, X.; Mowry, E.M.; Sorensen, P.S.; Tintoré, M.; Traboulsee, A.L.; Trojano, M.; Uitdehaag, B.M.J.; Vukusic, S.; Waubant, E.; Weinshenker, B.G.; Reingold, S.C.; Cohen, J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol., 2018, 17(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(17)30470-2] [PMID: 29275977]
[16]
Available from:https://www.neurostatus.net/
[17]
Available from:https://www.salute.gov.it/portale/nuovocorona-virus/dettaglioFaqNuovoCoronavirus.jsp?lingua=english&id=230
[18]
Sahi, N.K.; Abidi, S.M.A.; Salim, O.; Abraham, R.; Kalra, S.; Al-Araji, A. Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation. Mult. Scler. Relat. Disord., 2021, 56, 103287.
[http://dx.doi.org/10.1016/j.msard.2021.103287] [PMID: 34627005]
[19]
van Lierop, Z.Y.G.J.; Toorop, A.A.; van Ballegoij, W.J.C.; Olde Dubbelink, T.B.G.; Strijbis, E.M.M.; de Jong, B.A.; van Oosten, B.W.; Moraal, B.; Teunissen, C.E.; Uitdehaag, B.M.J.; Killestein, J.; Kempen, Z.L.E. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult. Scler., 2022, 28(7), 1121-1125.
[http://dx.doi.org/10.1177/13524585211028833] [PMID: 34240631]
[20]
Zanghì, A.; Avolio, C.; Signoriello, E.; Abbadessa, G.; Cellerino, M.; Ferraro, D.; Messina, C.; Barone, S.; Callari, G.; Tsantes, E.; Sola, P.; Valentino, P.; Granella, F.; Patti, F.; Lus, G.; Bonavita, S.; Inglese, M.; D’Amico, E. Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? evidence from an italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics, 2022, 19(5), 1535-1545.
[http://dx.doi.org/10.1007/s13311-022-01289-6] [PMID: 36036858]
[21]
Montalban, X.; Hauser, S.L.; Kappos, L.; Arnold, D.L.; Bar-Or, A.; Comi, G.; de Seze, J.; Giovannoni, G.; Hartung, H.P.; Hemmer, B.; Lublin, F.; Rammohan, K.W.; Selmaj, K.; Traboulsee, A.; Sauter, A.; Masterman, D.; Fontoura, P.; Belachew, S.; Garren, H.; Mairon, N.; Chin, P.; Wolinsky, J.S. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med., 2017, 376(3), 209-220.
[http://dx.doi.org/10.1056/NEJMoa1606468] [PMID: 28002688]
[22]
D’Amico, E.; Patti, F.; Zanghì, A.; Zappia, M. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int. J. Mol. Sci., 2016, 17(10), 1725.
[http://dx.doi.org/10.3390/ijms17101725] [PMID: 27763513]
[23]
Zanghì, A.; D’Amico, E.; Luca, M.; Ciaorella, M.; Basile, L.; Patti, F. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult. Scler. Relat. Disord., 2020, 46, 102561.
[http://dx.doi.org/10.1016/j.msard.2020.102561] [PMID: 33045494]
[24]
van Kempen, Z.L.E.; Hoogervorst, E.L.J.; Wattjes, M.P.; Kalkers, N.F.; Mostert, J.P.; Lissenberg-Witte, B.I. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology, 2020, 95(6), e745-e754.
[http://dx.doi.org/10.1212/WNL.0000000000009995] [PMID: 32690785]
[25]
Ellrichmann, G.; Bolz, J.; Peschke, M.; Duscha, A.; Hellwig, K.; Lee, D.H.; Linker, R.A.; Gold, R.; Haghikia, A. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J. Neurol., 2019, 266(1), 57-67.
[http://dx.doi.org/10.1007/s00415-018-9092-4] [PMID: 30377816]
[26]
Benkert, P.; Meier, S.; Schaedelin, S.; Manouchehrinia, A.; Yaldizli, Ö.; Maceski, A.; Oechtering, J.; Achtnichts, L.; Conen, D.; Derfuss, T.; Lalive, P.H.; Mueller, C.; Müller, S.; Naegelin, Y.; Oksenberg, J.R.; Pot, C.; Salmen, A.; Willemse, E.; Kockum, I.; Blennow, K.; Zetterberg, H.; Gobbi, C.; Kappos, L.; Wiendl, H.; Berger, K.; Sormani, M.P.; Granziera, C.; Piehl, F.; Leppert, D.; Kuhle, J.; Aeschbacher, S.; Barakovic, M.; Buser, A.; Chan, A.; Disanto, G.; D’Souza, M.; Du Pasquier, R.; Findling, O.; Galbusera, R.; Hrusovsky, K.; Khalil, M.; Lorscheider, J.; Mathias, A.; Orleth, A.; Radue, E-W.; Rahmanzadeh, R.; Sinnecker, T.; Subramaniam, S.; Vehoff, J.; Wellmann, S.; Wuerfel, J.; Zecca, C. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol., 2022, 21(3), 246-257.
[http://dx.doi.org/10.1016/S1474-4422(22)00009-6] [PMID: 35182510]